» Articles » PMID: 12789289

Role and Regulation of the Thrombin Receptor (PAR-1) in Human Melanoma

Overview
Journal Oncogene
Date 2003 Jun 6
PMID 12789289
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

To determine treatment strategies and predict the clinical outcome of patients with melanoma it is important to understand the etiology of this disease. Recently, there has been some insight into molecular basis of melanoma including identification of a few of the regulatory factors and genes involved in this disease. For instance, the transcription factor AP-2 plays a tumor suppressor-like role in melanoma progression by regulating genes involved in tumor growth and metastasis. Previously, we have shown that the progression of human melanoma to the metastatic phenotype is associated with loss of AP-2 expression and deregulation of target genes such as MUC18/MCAM, c-KIT, and MMP-2. Increasing evidence demonstrates that the thrombin receptor (protease-activated receptor-1, PAR-1) plays a major role in tumor invasion and contributes to the metastatic phenotype of human melanoma. This review focuses on the role of the thrombin receptor in melanoma and its regulation by AP-2. We show that loss of AP-2 expression in metastatic melanoma cells correlates with overexpression of the thrombin receptor. Our analysis of AP-2/Sp1 complexes within the regulatory region of the thrombin receptor demonstrates that AP-2 binds the proximal 3' region of the promoter and diminishes PAR-1 expression. Levels of AP-2 and Sp1 proteins in a panel of melanoma cell lines demonstrated a marked decrease in the ratio of AP-2/Sp1, a decrease that correlated with overexpression of PAR-1 in metastatic melanoma cells. We propose that loss of AP-2 results in increased expression of the thrombin receptor, which subsequently contributes to the metastatic phenotype of melanoma by upregulating the expression of adhesion molecules, proteases, and angiogenic molecules.

Citing Articles

Coagulation factor II thrombin receptor as a promising biomarker in breast cancer management.

Dong Y, Bao G Open Life Sci. 2024; 19(1):20221001.

PMID: 39655193 PMC: 11627072. DOI: 10.1515/biol-2022-1001.


Bioinformatics analysis identifies coagulation factor II receptor as a potential biomarker in stomach adenocarcinoma.

Wu X, Wang S, Wang C, Wu C, Zhao Z Sci Rep. 2024; 14(1):2468.

PMID: 38291086 PMC: 10827804. DOI: 10.1038/s41598-024-52397-6.


Impaired activation of plasmacytoid dendritic cells toll-like receptor 7/9 and STING is mediated by melanoma-derived immunosuppressive cytokines and metabolic drift.

Monti M, Ferrari G, Grosso V, Missale F, Bugatti M, Cancila V Front Immunol. 2024; 14:1227648.

PMID: 38239354 PMC: 10795195. DOI: 10.3389/fimmu.2023.1227648.


The environmental carcinogen benzo[a]pyrene regulates epigenetic reprogramming and metabolic rewiring in a two-stage mouse skin carcinogenesis model.

Sarwar M, Ramirez C, Kuo H, Chou P, Wu R, Sargsyan D Carcinogenesis. 2023; 44(5):436-449.

PMID: 37100755 PMC: 10414144. DOI: 10.1093/carcin/bgad024.


Discovery of Screening Biomarkers for Major Depressive Disorder in Remission by Proteomic Approach.

Choi H, Mun S, Joo E, Lee K, Kang H, Lee J Diagnostics (Basel). 2021; 11(3).

PMID: 33802981 PMC: 8002827. DOI: 10.3390/diagnostics11030539.